Nhin Lu - Concepedia

Author

Nhin Lu

Also Known As

N N Lu, N. Lu, Nhin Lu

Publications

Citations

H-Index

Concepts

All Affiliations

Nhin Lu is an author at Edison Pharmaceuticals (United States) specializing in radiation oncology, breast cancer, and medicine.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	444
2	Pharmacology	4	4	444
3	Cancer Cell Biology	2	2	154
4	Cancer Therapeutics	2	2	154
5	Cell Biology	1	1	117

Nhin Lu

Publications

Citations

H-Index

Page 1

	Year	Citations
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 James D. Joseph, Nhin Lu, Jing Qian, Cancer Discovery	2013	570
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts Andiliy Lai, Mehmet Kahraman, Steven P. Govek, Journal of Medicinal Chemistry Breast OncologyChemoprevention StrategyPharmacotherapyLead Compound 11LTumor Biology	2015	244
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer James D. Joseph, Beatrice Darimont, Wei Zhou, eLife Diverse ModelsBreast OncologyErα SignalingCancer Cell BiologyAnti-cancer Agent	2016	117
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft Steven P. Govek, Johnny Nagasawa, Karensa Douglas, Bioorganic & Medicinal Chemistry Letters Tumor RegressionBreast OncologyOncologyMedicineHormonal Receptor	2015	46
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer Johnny Nagasawa, Steven P. Govek, Mehmet Kahraman, Journal of Medicinal Chemistry Breast OncologyChemoprevention StrategyPharmacotherapyTumor BiologyMolecular Pharmacology	2018	37

Page 1